Skip to main content

Dulaglutide News

26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024

THURSDAY, Aug. 14, 2025 – In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by...

GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy

TUESDAY, Aug. 12, 2025 – For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic...

Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults

THURSDAY, Aug. 7, 2025 – A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have...

GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy

TUESDAY, Aug. 5, 2025 – For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION),...

ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM

FRIDAY, April 4, 2025 – For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and...

GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes

FRIDAY, Dec. 6, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes,...

Stroke Guidelines Updated, With Focus on Women and GLP-1s

MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...

Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption

THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....

More Evidence That GLP-1 Meds Curb Alcohol Abuse

FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...

Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period

TUESDAY, Nov. 5, 2024 – In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of...

ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer

FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...

FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...

Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity

TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...

GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies

FRIDAY, Oct. 4, 2024 – Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic...

FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions

ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Cardiovascular Risk Reduction, Diabetes, Type 2, Weight Loss (Obesity / Overweight)

Related drug support groups

Trulicity

Dulaglutide patient information at Drugs.com